Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T19:53:30.092Z.
Calculation as of: 2026-10-06T19:53:30.092Z.
Quote observation: 2026-10-06T19:48:55.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 41380868948bde6df6f28b5310a55e7ea83c2eaa443efb93c39b202ec723f694
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Processa Pharmaceuticals, Inc.
Market Cap
$4.04M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.87M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.27M
Price/OCF Ratio
N/A
TTM Avg
35.59
3Y Avg
35.59
5Y Avg
35.59
Market Cap
$3.63M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | $4.04M | N/A | N/A | N/A | N/A |
| Aptevo Therapeutics Inc. (APVO)vs › | $3.98M | N/A | N/A | N/A | N/A |
| 60 Degrees Pharmaceuticals, Inc. (SXTP)vs › | $3.87M | N/A | N/A | N/A | N/A |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.27M | N/A | 35.59 | 35.59 | 35.59 |
| GRI Bio, Inc. (GRI)vs › | $4.27M | N/A | N/A | N/A | N/A |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.33M | N/A | N/A | N/A | N/A |
| Evogene Ltd. (EVGN)vs › | $3.66M | N/A | N/A | N/A | N/A |
| Eocene Ltd. (EOCN)vs › | $3.64M | N/A | N/A | N/A | N/A |
| WORK Medical Technology Group Ltd. Class A (WOK)vs › | $3.63M | N/A | N/A | N/A | N/A |
| Ernexa Therapeutics Inc. (ERNA)vs › | $3.61M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
